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Alloimmunity and tolerance in corneal transplantation
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Abstract
Corneal transplantation is one of the most prevalent and successful forms of solid tissue 
transplantation. Despite favorable outcomes, immune-mediated graft rejection still remains the 
major cause of corneal allograft failure. While ‘low risk’ graft recipients with uninflamed graft 
beds enjoy a success rate of approximately 90%, the rejection rates in inflamed graft beds or ‘high 
risk’ recipients often exceed 50% despite maximal immune suppression. In this review we discuss 
the critical facets of corneal alloimmunity, including immune and angiogenic privilege, 
mechanisms of allosensitization, cellular and molecular mediators of graft rejection, and 
allotolerance induction.
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Introduction
More than a century has passed since Eduard Zirm, an Austrian ophthalmologist, performed 
the first partially successful full-thickness human corneal transplant (1). Today, corneal 
transplantation is one of the most prevalent forms of solid tissue transplantation performed 
in the world (2). It is estimated that well over 100 000 corneal transplant surgeries are 
performed annually worldwide, with nearly 40 000 performed annually in the United States 
alone (3). Several trends are notable. First, the number of corneal grafts performed in the 
developing world, especially Asia, is rising sharply due to enhanced eye banking procedures 
and distribution networks. Second, partial-thickness corneal transplants (lamellar 
keratoplasty) are increasingly being used in place of full-thickness transplants (penetrating 
keratoplasty) when the entire cornea does not need to be replaced, and this trend has led to 
some decreased risk of graft rejection, likely due to decreased load of allogeneic tissue (4, 
5). Still, it is critical to emphasize that the most important prognosticator of graft success is 
the status of the recipient bed in which the corneal graft is placed. The 2-year graft survival 
for penetrating keratoplasty in non-vascularized and uninflamed host beds or ‘low risk’ 
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corneal transplants is approximately 90% (6). However, recipients with a previous history of 
graft rejection or grafts performed in inflamed and vascularized host beds are considered to 
be at high risk of rejection, with failure rates of over 50% despite maximal local and 
systemic immunosuppressive therapy (7) – outcomes that are considerably worse than 
kidney, heart or liver transplants. Interestingly, the remarkable rate of success normally seen 
in low-risk corneal grafts, unlike other solid transplants, is achievable without the benefit of 
HLA matching or profound systemic immune suppression (7).
Despite these favorable outcomes, graft rejection remains the leading cause of corneal 
allograft failure (8). Corneal graft rejection can occur in any of the three cell layers of the 
cornea–epithelium, stroma or endothelium, with endothelial rejection being the most 
prevalent sight-threatening form, which can be attributed to the fact that the endothelial cells 
of the cornea are irreplaceable, and perform the critical function of preventing the tissue 
from getting swollen (9). Graft rejection is clinically characterized by graft edema (swelling) 
and inflammatory cells that can be seen circulating in the anterior chamber of the eye or 
attaching as keratic precipitates to the graft endothelial cells (Fig 1A) (10). Several factors 
have been associated with a higher risk of graft failure, with the degree of host bed 
neovascularization being the most significant prognosticator for earlier and a more severe 
graft rejection (7, 11, 12).
In this review, we discuss the factors involved in ocular inflammation, activation and 
migration of antigen-presenting cells (APCs), pathways of allosensitization and 
allotolerance, and mechanisms of graft destruction (Fig 1B).
Immune and angiogenic privilege of the cornea and their implications in transplant 
immunity
The term “immune privilege” was first coined by Sir Peter Medawar in the late 1940s, when 
he recognized the extended survival of skin allografts placed in the anterior chamber of the 
eye (13). He attributed this unexpected graft survival to what he considered to be 
“immunological ignorance”, a passive process of sequestration of foreign antigens in the 
anterior chamber due to the absence of draining lymphatic vessels. However, later in the 
1970s, Kaplan and Streilein demonstrated that immune privilege was in fact the result of an 
actively maintained and “deviant” suppressive immune response to ocular antigens (14), a 
phenomenon that was later referred to as anterior chamber-associated immune deviation 
(ACAID) (15).
Immune Privilege—ACAID is a form of immune tolerance to alloantigens placed in the 
anterior chamber of the eye that results in downregulation of antigen-specific delayed type 
hypersensitivity (DTH) response, while promoting humoral immunity and production of 
non-complement fixing antibodies (16). This process is thought to be mediated by 
F4/80+APCs in the eye that capture intraocular antigens, enter the bloodstream and migrate 
to the marginal zone of the spleen, where their interactions with CD4+ T cells, γδT cells, B 
cells, and natural killer (NK) T cells result in the generation of two groups of antigen-
specific regulatory T cells (Tregs): CD4+ CD25+ Tregs and CD8+ Tregs (17). Studies on the 
implication of ACAID in murine models of corneal transplantation have demonstrated that 
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ACAID induction through intraocular injection of allogeneic lymphocytes prior to 
penetrating keratoplasty causes a significant improvement in corneal allograft survival (18, 
19).
Aside from immunological tolerance induced by ACAID, several other mechanisms 
contribute to the maintenance of ocular immune privilege (Table 1). The cornea expresses an 
array of membrane-bound immunomodulatory molecules that protect the cornea from 
inflammation and promote immune quiescence. Programmed death ligand-1 (PDL-1) is a 
pro-apoptotic molecule, which is constitutively expressed at high levels by the cornea (20, 
21). PDL-1 interaction with PD-1 receptor on T cells results in inhibition of T cell 
proliferation, apoptosis induction and inhibition of IFNγ production leading to prolonged 
allograft survival (20, 22). Recent studies have established distinct mechanisms for donor 
and host derived PDL-1 in promoting corneal allograft survival. Depletion of PDL-1 in graft 
recipients results in considerably stronger indirect T cell priming and rapid graft rejection 
than wild-type recipients (20). Elimination of PDL-1 in the graft donor, however, does not 
have a significant effect on indirect allorecognition, but results in an increased alloreactive T 
cell infiltration and graft failure (20). IL-1Ra, which is constitutively expressed by the 
cornea, promotes immune privilege through suppression of antigen-presenting cell migration 
to the cornea (23). Topical administration of IL-1Ra has been shown to promote allograft 
survival in both low risk and high risk graft recipients in a murine model of corneal 
transplantation (24). Thrombospondin-1 (TSP-1) is an immunomodulatory glycoprotein 
expressed by the cornea and immune cells such as APCs. Studies have demonstrated 
significantly higher rates of graft rejection in TSP-1 null mouse corneal allografts compared 
to wild-type grafts (25). APC-derived TSP-1 inhibits maturation of APCs during 
inflammation, regulates their migration to draining lymph nodes, and suppresses their 
capacity in direct sensitization of alloreactive T cells (25). Corneal epithelial and endothelial 
cells constitutively express the pro-apoptotic molecule FasLigand (CD95L). Interaction of 
FasLigand with Fas (CD95)-expressing inflammatory cells such as neutrophils and effector 
T cells results in their apoptotic death, thereby improving allograft survival (26). Tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) is a transmembrane 
protein highly homologous with FasL which is constitutively expressed by corneal cells 
(27). TRAIL has been implicated in apoptosis of activated T cells and has been found to 
promote the proliferation of Tregs (28). Although no studies have directly associated TRAIL 
expression with corneal graft survival, transfection of mouse donor corneas with adenovirus 
carrying TRAIL gene has been shown to significantly improve corneal allograft survival 
(29). In addition to these membrane-bound proteins, several soluble immunoregulatory 
factors are found in the aqueous humor of the eye including TGF-β2, complement regulatory 
proteins (CRP), alpha-melanocyte stimulating hormone (α-MSH), vasoactive intestinal 
peptide (VIP), calcitonin gene-related peptide (CGRP), somatostatin, macrophage migration 
inhibitory factor (MIF) and indoleamine 2, 3-dioxygenase (IDO), which are involved in 
tolerance induction in macrophages, regulation of dendritic cells, and inhibition of 
complement and NK cell-mediated cell lysis and T cell activation (30–39).
Angiogenic Privilege—The cornea is devoid of vasculature and lymphatics, which limits 
the trafficking of immune cells between the cornea and the systemic circulation and 
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lymphoid organs. This “angiogenic privilege” is actively maintained through expression of 
several anti-angiogenic factors. Corneal epithelial cells constitutively secrete soluble 
VEGFR-1 which binds VEGF-A, and thus inhibits its mitogenic effect on vascular 
endothelial cells (40). Additionally, non-signaling VEGFR-3, which is constitutively 
expressed by the corneal epithelium, demonstrates antiangiogenic activity by acting as a 
decoy receptor for VEGF-C and VEGF-D (41, 42), thereby suppressing both blood and 
lymphatic vessel growth. Studies on a mouse model of corneal transplantation have also 
demonstrated that blockade of VEGFR-3 or VEGFR-3 binding ligands such as anti-VEGF-C 
results in significant inhibition of lymphangiogenesis and ultimately prolonged corneal graft 
survival (43). Corneal epithelial cells additionally express soluble VEGFR-2 that inhibits 
VEGF-C and thus blocks lymphangiogenesis (44). Intracorneal administration of soluble 
VEGFR-2 has been shown to double allograft survival in a mouse model of corneal 
transplantation (44). Other anti-angiogenic factors that are expressed by the cornea include 
(i) angiostatin, which inhibits vascular endothelial cell proliferation and migration (45); (ii) 
endostatin, which blocks the mitogenic activity of VEGF on vascular endothelial cells and 
promotes their apoptosis (46); (iii) pigment epithelium-derived factor (PEDF) expressed by 
corneal epithelium and endothelium that exerts its anti-angiogenic effect through 
downregulation of VEGF expression (47); and (iv) thrombospondin-1 (TSP-1), which 
inhibits hemangiogenesis and lymphangiogenesis by induction of vascular endothelial cell 
apoptosis and CD36-mediated downregulation of VEGF-C (48). Results of a recent study 
have shown that subconjunctival administration of endostatin to mice undergoing corneal 
transplantation inhibits graft neovascularization and T cell infiltration, and significantly 
prolongs corneal graft survival (49). It has also recently been demonstrated that PD-L1 has 
anti-angiogenic functions (50). Suture-induced corneal inflammation in PD-L1 knock out 
mice results in a more significant angiogenic response and higher levels of VEGFR-2 
expression compared to wild-type mice (50). This complex interplay between anti- and pro-
angiogenic factors demonstrates the importance of regulation of hem- and 
lymphangiogenesis in the maintenance of corneal immune privilege.
Relevance of major histocompatibility complex (MHC) antigens in corneal alloimmunity
All corneal cells including epithelial, stromal and endothelial cells express MHC class I 
antigens. Interestingly, in the healthy cornea only DCs in the peripheral cornea express 
MHC class II, while DCs and other myeloid cell populations residing in the center of the 
cornea express minimal to no levels of MHC class II (51). In contrast to their kin in the skin, 
inflammatory stresses induce MHC class II expression by the significant majority of corneal 
DCs and corneal epithelial cells (30).
HLA (MHC) matching along with systemic immunosuppression are the cornerstones of 
prophylactic strategies against rejection for solid organ transplants such as the kidney; 
however, neither is routinely performed in corneal transplantation. A myriad of studies have 
been performed since the 1970s on relative efficiency of HLA matching in corneal allograft 
survival. The results from these studies have been mixed, with some studies showing a clear 
benefit (52, 53). However, the largest prospective randomized study of HLA matching in 
corneal transplantation in the United States, the Collaborative Corneal Transplantation 
Studies (CCTS), showed no benefit for HLA-DR matching (7). Evidence regarding the 
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effect of MHC class II/HLA-DR matching remains unclear. Many studies have demonstrated 
prolonged survival rates in grafts with lower number of HLA-DR mismatches, especially in 
the high-risk setting (52, 54). This is in contrast with the CCTS, which reported no 
significant difference in graft rejection rates between cross-matched and non HLA-matched 
groups (7). The failure of CCTS to demonstrate beneficial results for HLA-matching on 
graft survival has been attributed to various factors, including the possibility of incorrect 
typing (these studies were primarily done in the 1980s before the advent of DNA-based 
typing methods) and aggressive immunosuppressive therapy regimens that can nullify the 
beneficial effects of HLA matching, in part by suppressing MHC expression (55). The 
CCTS, however, reported that matching for minor histocompatibility antigens such as ABO 
group may improve graft survival. In humans, donor-recipient matching of minor H-Y 
antigen has recently been associated with significantly lower graft rejection rates (56). The 
role of minor histocompatibility antigens is more prominent in low risk corneal transplants, 
where resident corneal APCs express minimal levels of MHC class II, as described above. 
However, significantly increased expression of MHC class II and co-stimulatory molecules 
(e.g. CD80, CD86, CD40) by graft APCs in inflamed host beds leads to activation of the 
direct pathway of allosensitization, further underscoring the possible utility of MHC 
matching in the high-risk setting (57, 58). Despite the preponderancy of data suggesting that 
MHC class II matching can enhance corneal allograft survival in high risk grafts, it is likely 
that given its high economic costs, the debate regarding the merits of MHC matching in 
corneal transplantation will continue until large randomized clinical trials using modern 
DNA-based typing methods provide more definitive answers.
Mechanisms of allosensitization: significance of direct versus indirect allorecognition 
pathways
Corneal graft rejection is a complex process during which changes in the corneal 
microenvironment and the interplay between cells of the innate and adaptive immunity result 
in graft destruction. Early after transplantation, ocular surface inflammation leads to 
upregulation of proinflammatory cytokines such as IL-1, IL-6, and TNF-α (59), chemokines 
including MIP-1α, MIP-1β, MIP-2, and RANTES (60), and overexpression of adhesion 
molecules such as ICAM-1 and VLA-1 (61–63). This inflammatory milieu results in the 
acquisition of high levels of MHC class II and costimulatory molecules such as CD80 
(B7-1), CD86 (B7-2), and CD40 by resident and infiltrating host APCs. Under these 
circumstances, donor corneal APCs, which normally lack the capacity to stimulate T cells, 
become more potent in alloantigen presentation and priming of naïve T cells into Th1 
effectors, the principal mediators of acute corneal graft rejection (see below for details of 
effector mechanisms) (10, 64, 65). Additionally, inflammation-induced expression of 
adhesion molecules and chemotactic gradient assist in mobilizing host APCs from the peri-
corneal limbal vasculature centripetally toward the corneal graft (64, 66).
The cornea is normally devoid of both blood and lymphatic vessels. However, ocular 
inflammation leads to formation of blood and lymphatic neovessels. Inhibition of heme- and 
lymphangiogenesis in high-risk recipient mice has been shown to improve corneal allograft 
survival (43, 44, 67). The pathologic corneal lymphangiogenesis that occurs due to 
inflammation facilitates APC migration to draining lymph nodes, where they prime 
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alloreactive T cells (30). Expression of inflammatory cytokines, adhesion molecule ICAM-1, 
and CCL2 and CCL20 chemokines facilitate corneal infiltration of innate immune cells, 
which promote lymphangiogenesis through production of VEGF-C and VEGF-D (61, 68–
71). It has been demonstrated that APCs, as a part of their “maturation” process also acquire 
VEGFR-3 expression, which in response to the chemotactic gradient of its principal receptor 
VEGF-C mediates APC trafficking to lymphoid tissues (72). APC migration through 
afferent lymphatic vessels is also dependent on the interaction between the CCR7 receptor 
and its ligand CCL21, which is expressed by lymphatic endothelial cells during 
inflammation, and APC interactions with ICAM-1 and VCAM-1 adhesion molecules (73, 
74). The importance of lymphatic vessels in allosensitization is underscored by significantly 
higher APC trafficking and higher rejection rates seen in neovascularized or high-risk 
corneal graft beds that are lymphatic-rich compared to low-risk hosts (75, 76). Moreover, 
limiting the access of APCs to draining lymph nodes via ipsilateral cervical 
lymphadenectomy prior to transplantation has been shown to significantly prolong corneal 
allograft survival in murine models (77), providing proof of concept for the importance of 
lymphatics in facilitating allosensitization.
Allosensitization or priming of alloreactive T cells occurs via two distinct pathways. The 
direct pathway of allosensitization involves presentation of donor antigens in the context of 
non-self MHC by donor-derived APCs or “passenger leukocytes” to host naïve T cells (58). 
In the indirect pathway, however, host APCs recruited from the peripheral cornea (recipient 
bed) present donor antigens in association with self-MHC to naïve T cells in the draining 
lymph nodes (58). It was previously believed that the indirect pathway of allosensitization is 
the predominant, if not exclusive, form of immune response in all corneal transplants (78). 
However, identification of diverse populations of bone marrow-derived cells in the cornea 
that can acquire MHC class II expression under inflammatory conditions and thus serve as 
functional APC has further strengthened the functional role of direct alloreactivity in corneal 
transplantation (65, 79). Furthermore, accumulating data suggest that the relevance of direct 
or indirect pathways is highly dependent on graft bed microenvironment (58). In the non-
inflamed setting where there is minimal expression of graft-derived MHC molecules, the 
indirect pathway remains predominant; however, in the high risk setting, characterized by 
graft bed inflammation and acquisition of high levels of MHC and accessory molecules by 
graft-borne APCs, the direct pathway is highly functional (Fig 2) (58, 80, 81). It has been 
demonstrated that the use of MHC class II-deficient donor tissue results in considerably 
prolonged survival of high-risk, but not low-risk corneal grafts (58), further underscoring the 
relevance of the direct pathway in high risk transplantation.
Effector immune cells and mechanisms of graft destruction
IFNγ-producing CD4+ Th1 cells are considered to be the predominant effector cells in 
corneal graft rejection (82, 83), but the precise mechanisms by which Th1 cells mediate graft 
rejection have not been fully elucidated. Although in vitro studies have demonstrated that 
alloreactive CD4+ T cells induce apoptosis in corneal endothelial cells (84), in vivo 
application of anti-FasL antibody or Fas-Fc protein does not inhibit CD4 T-cell mediated 
apoptosis of corneal cells (82). High expression of IFNγ and IL-2 in corneas undergoing 
rejection further supports the central role of Th1 cells in corneal allograft rejection (85, 86). 
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However, 33% of anti-CD4 antibody-treated mice and 45% of CD4 knock out mice still 
reject their corneal allografts, indicating that CD4-independent mechanisms are also 
involved in graft rejection (83, 85). In addition, studies on the rate of graft rejection in IFNγ 
knock out mice have demonstrated that 70% of MHC-mismatched grafts and none of MHC-
matched grafts undergo rejection, suggesting that Th1 cells are not the sole mediators of 
graft rejection (87, 88).
It has long been proposed that skewing the immune system toward a Th2 alloimmune 
response promotes corneal allograft survival. Yamada et al. found that ‘deviation’ of the 
alloimmune response toward a Th2 phenotype promotes corneal allograft survival in a 
murine model of orthotopic corneal transplantation (89). However, recent studies have 
demonstrated higher rates of corneal allograft rejection in graft recipients with atopic 
(allergic) conjunctivitis, a disorder which is primarily mediated through a Th2 immune 
response (90, 91). Furthermore, it has been demonstrated that corneal graft rejection in IFNγ 
knock out mice is characterized by eosinophilic corneal infiltrates and is mediated by the 
Th2 pathway (87). Thus, in the aggregate, while there is general consensus that Th1 cells are 
the principal effectors of acute corneal graft rejection, it is clear that depletion of CD4+ T 
cells or IFNγ is unable to entirely suppress alloreactivity, thereby suggesting the 
involvement of myriad effector pathways including CD8+ and Th2 cells.
Involvement of Th17 cells has been established in the pathogenesis of multiple autoimmune 
diseases, including chronic ocular inflammatory conditions (92, 93). In transplant 
immunobiology, Th17 cells have been implicated in the development of lung and renal 
allograft rejection and graft-versus-host disease (94–96). Murine models of orthotopic 
corneal transplantation have revealed that the pathogenic role of Th17 cells is more evident 
at the very early stages of graft rejection, while IFNγ–producing Th1 cells are 
predominantly involved in later stages, and are critical for eventual graft rejection (97). The 
pro-lymphangiogenic role of Th17 cells has also been demonstrated in a murine model of 
autoimmune ocular surface inflammatory disease (98) indicating that blocking the effect of 
IL-17 may favor corneal allograft survival. However, approximately 90% of corneal 
allografts in IL-17−/− mice or wild-type mice treated with anti-IL-17 antibody still reject 
their allografts (97, 99). Interestingly, IL-17 deficiency retards the development of 
alloimmune rejection in these hosts, and promotes the expression of Th2 type cytokines, 
IL-4, IL-5, and IL-13 (97). These data along with observations on corneal graft rejection in 
IFNγ knock out mice suggest that elimination of Th1 and Th17 pathways results in a Th2-
biased immune response, and that deviating the host’s immune response toward a Th2 
phenotype, contrary to previous dogma, may in fact have a deleterious effect on corneal 
allograft survival (88, 97, 99). There has also been compelling evidence that IL-17 promotes 
the generation of CD4+CD25+Foxp3+ Tregs in corneal allografts, and is required for Tregs 
to exert their immunosuppressive function on effector CD4+ T cells (100).
Studies on the role of CD8+ or cytotoxic T cells in graft rejection have yielded controversial 
results as well. While some murine studies have suggested a role for donor-specific CD8+ T 
cells in high risk grafts, other studies have demonstrated that corneal allograft rejection 
occurs invariably in CD8+ T cell-deficient and perforin-deficient mice (101, 102). Overall 
results suggest that a CD8+ T cell response is not absolutely essential for corneal allograft 
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rejection. Although priming of CD8+ T cells occurs, in the absence of costimulatory signals 
from APCs, CD8+ T cells do not have the ability to reject the graft (103). CD8+ suppressor 
T cells (CD8+ Tregs), which are generated during the induction of ACAID, have been shown 
to suppress allospecific DTH response via perforin and FasL-independent mechanisms, 
promoting corneal immune privilege (104). Another subset of T cells, double negative or 
CD4−CD8− T cells, has also been implicated in corneal graft rejection through apoptosis of 
corneal endothelium (102, 105). Adoptive transfer of CD4−CD8− T cells to mice with severe 
combined immunodeficiency (SCID) results in acute corneal allograft rejection (102). 
However, the precise role of these cells as effector cells in mediating graft rejection is yet to 
be elucidated.
Allotolerance induction: contribution of regulatory T cells to allograft survival
One of the primary goals in transplant immunobiology is donor-specific tolerance induction 
which eliminates the need for immunosuppressive therapies and promotes graft survival. 
Tolerogenic Tregs and DCs are potential candidates that can be exploited for the induction of 
allotolerance in corneal transplantation. Maturation-resistant tolerogenic DCs (tolDCs), 
which express low levels of MHC class II and co-stimulatory molecules, have been 
implicated in suppression of alloimmunity and promotion of graft survival in multiple solid 
organ transplant models (106–108). Studies on murine models of penetrating keratoplasty 
have demonstrated that administration of donor-derived tolDCs to hosts prior to 
transplantation increases the frequencies of Foxp3hi Tregs and significantly improves 
corneal allograft survival (109). Results of a recent study indicate that the beneficial effect of 
tolDCs on corneal graft survival is mediated through expansion of CTLA-4 expressing Tregs 
and downregulation of CD28+ Tregs (110). Given that tolDCs induce allotolerance primarily 
through Treg expansion, the majority of studies have focused on modification of Treg 
function to promote graft survival.
A myriad of studies have focused on the role of Tregs in allotolerance induction and in vitro 
expansion of Tregs to promote allograft survival (111, 112). Compelling evidence suggest 
that corneal allograft-induced donor specific Tregs are capable of suppressing the DTH 
immune response and enhancing allograft survival (99, 100, 112, 113). Generation and 
expansion of Tregs within the corneal allograft has been found to be mediated by the 
glucocorticoid-induced tumor necrosis factor receptor family-related protein ligand 
(GITRL), which is constitutively expressed in the cornea (114). Studies on the suppressive 
function of Tregs have revealed that Treg-mediated suppression of effector T cells is 
primarily contact-dependent and mediated by membrane-bound GITRL and CTLA-4 
molecules (100). Additionally, IL-17 regulates the expression of Foxp3 and these 
membrane-bound molecules on Tregs (100). As mentioned above, IL-17 is required for the 
generation of Tregs, and treatment with an anti-IL-17 antibody results in rejection of 90% of 
corneal allografts (100). Although previously non-ocular allograft survival was associated 
with increased frequencies of Tregs within the graft or the draining lymph nodes (115), a 
recent study has reported no difference in frequencies, but higher levels of Foxp3 expression 
in the draining lymph node Tregs of accepted corneal allografts compared to allografts 
undergoing rejection (Fig 3A) (116). The suppressive function of Tregs has been related to 
their expression of Foxp3 (Fig 3B) (116, 117). Moreover, it has been demonstrated that 
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Foxp3hi Tregs from accepted grafts are more potent in suppressing naïve T cell proliferation 
and secreting IL-10 and TGF-β (116). Studies on homing of Tregs to draining LNs of 
corneal allograft recipients and their interaction with APCs (Fig 3C) have shown that: (i) 
Tregs from allograft acceptors localize in the paracortical region of draining LNs in close 
proximity with APCs and express higher levels of CCR7, while Tregs from graft rejectors 
express lower levels of CCR7 and are less in contact with APCs, (ii) CCR7hi Tregs have a 
more significant inhibitory effect on T cell proliferation and secrete higher levels of 
immunosuppressive cytokines, and (iii) in vitro stimulation of naïve Tregs with CCL21 
upregulates their CCR7 expression and improves Tregs’ homing ability to draining lymph 
nodes and significantly enhances corneal allograft survival (Fig 3D) (118). These data 
accumulatively suggest that Tregs become dysfunctional in grafts undergoing rejection. A 
recent study from our laboratory has shown that Treg dysfunction can be prevented by 
systemic administration of low-dose IL-2. Our data have demonstrated that systemic 
treatment of high risk recipient mice with low-dose IL-2 results in expansion and improved 
suppressive function of Tregs, reduced leukocyte infiltration of graft, and significantly 
improved corneal allograft survival (119).
Instability of Tregs or “Treg plasticity” in the inflammatory environment is a new concept 
that has recently gained attention. Recent data suggest that in the inflamed setting a 
significant number of Tregs exhibit unstable expressions of Foxp3; these “exTregs” acquire 
an effector memory T cell phenotype and produce IFNγ, which may further contribute to the 
development of autoimmunity (120). Recently our laboratory has employed a model of 
corneal transplantation in Foxp3-lineage reporter transgenic mice to evaluate the pathologic 
conversion of Tregs in immune privilege-disrupted (high risk) hosts. The results have 
suggested that ocular inflammation results in conversion of Tregs into IFNγ–producing 
exTregs. Neuropilin-1 (Nrp-1), a membrane-bound coreceptor which is selectively expressed 
on natural/thymic Tregs (tTregs) and not on peripherally induced Tregs (pTregs), was used 
to further determine the lineage of these exTregs (121). Our results demonstrated that 
Nrp-1− pTregs are more susceptible than Nrp-1+ tTregs to the effects of pro-inflammatory 
cytokines expressed in inflamed host beds, mediating their conversion into exTregs 
(unpublished data). These data suggest that the pathologic conversion of Tregs and their 
impaired function contribute to loss of corneal immune privilege and allograft rejection.
Conclusions
Corneal allograft rejection is a highly complex process that involves an elaborate interplay 
between cells of the innate and adaptive immunity and the lymphovascular system. Our 
understanding of immunology and pathophysiology of corneal allograft rejection has been 
considerably improved in recent years, and many of the recent investigations have focused 
on development of new therapies that could target the afferent and efferent arms of immunity 
at a molecular level, without compromising the integrity of the immune system. However, 
the redundancy of cellular and molecular pathways mediating graft rejection has made this a 
daunting task. Evolving strategies for allotolerance induction, primarily regulatory T cell-
based therapies are promising tools that could bring us closer to safe therapeutic modalities 
for corneal graft rejection.
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Figure 1. Immunobiology of corneal transplantation
A. Clinical manifestation of corneal graft rejection. Infiltrating monocytes and T cells attack 
the graft, often involving a rejection line that marches across the inner endothelial layer of 
the transplant, leaving an opaque and swollen graft behind. B. Schematic representation of 
corneal alloimmunity (I). Following transplant surgery, upregulation of pro-inflammatory 
cytokines, adhesion molecules and pro-angiogenic factors results in corneal infiltration of 
immune cells and formation of new blood and lymphatic vessels. (II). Antigen presenting 
cells (APCs), which acquire MHC class II and co-stimulatory molecules in the inflammatory 
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environment, egress from the cornea through lymphatic vessels to the draining lymph nodes, 
where they present alloantigens to naïve T cells (Th0). Newly formed lymphatic vessels may 
also contribute to resolution of inflammation by mediating clearance of inflammatory cells 
and debris. (III). Primed T cells undergo clonal expansion and differentiate primarily into 
IFNγ-secreting CD4+ Th1 cells. Regulatory T cells (Tregs) modulate induction of 
alloimmune response either through inhibition of T cell activation or suppression of APC 
stimulatory potential. (IV). Alloreactive Th1 cells, migrate through blood vessels and along 
a chemokine gradient toward the graft, where they mount a delayed-type hypersensitivity 
response against the allogeneic tissue, resulting in graft opacification and failure.
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Figure 2. Migration of donor graft-derived APCs and activation of the direct pathway of 
allosensitization
A. Ex vivo staining of corneal grafts with Hoechst vital dye tracks the egress of donor APCs 
posttransplantation. Stained isografts (BALB/c → BALB/c) demonstrates that ex vivo 
staining (blue; A1) is mostly restricted to the graft and not the host bed. In contrast, stained 
allografts (C57BL/6, IAb → BALB/c, IAd) evaluated at 24 h posttransplantation 
demonstrate that exiting donor cells in the host bed are largely CD45+ (red; A2) and express 
donor IAb (green; A3) (inlays are respective digitally enlarged portions of host beds). B. The 
frequencies of IFNγ-producing T cells 2 weeks after transplantation were assessed using 
ELISPOT. In high risk (HR) graft recipients, a significant higher IFNγ response is generated 
in directly primed allospecific T cells compared to low risk (LR) recipients and ungrafted 
controls (Naïve) (**p <0.01), suggesting that the direct alloresponse is the predominant form 
of allosensitization in the high-risk graft setting. Adopted and modified from Saban, D. R., 
et al.25 & Huq, S., et al.58
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Figure 3. Treg function and their interactions with antigen presenting cells in the draining lymph 
nodes of corneal allograft acceptors versus allograft rejectors
A. Mean fluorescent intensity (MFI) and Western blot analysis of Foxp3 expression in 
CD4+CD25+Foxp3+ Tregs from draining lymph nodes of allograft acceptors and rejectors 3 
weeks posttransplantation demonstrates significantly higher expression levels of Foxp3 in 
Tregs from graft acceptors compared to Tregs from grafts undergoing rejection. B. Tregs 
isolated from the lymph nodes of graft acceptors are significantly more potent in suppressing 
the proliferation of CD3-stimulated naïve T cells compared to Tregs isolated from lymph 
nodes of graft rejectors and syngeneic recipients. C. Confocal micrographs of draining 
lymph nodes show that only Tregs from graft acceptors colocalize with CD11c+ APCs 
(white arrows, 60×). D. Adoptive transfer of CCR7hi Tregs into corneal allograft recipients 
significantly improves corneal allograft survival (*p=0.022). Allograft recipients that receive 
CCR7lo Tregs demonstrate no improvement in allograft survival. Adopted and modified 
from Chauhan, S. K., et al.116, 118
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Table 1
Factors involved in immune and angiogenic privilege of the cornea
Factor* Function Reference
Angiostatin Inhibits vascular endothelial cell (VEC) proliferation 45
α-MSH Suppresses IFNγ production by T cells, Promotes Treg development 33, 38
CGRP Suppresses NO production by macrophages 35
CRP Inhibits activation of the complement system 32
Endostatin Promotes VEC apoptosis 46
FasLigand Promotes apoptosis of PMNs and T cells 26
IDO Promotes T cell apoptosis, Suppresses NK cell proliferation 39
IL-1Ra Suppresses APC migration 23
MIF Inhibits NK cell-mediated cytolysis of MHC class I-negative cells 36, 37
PDL-1 Promotes T cell apoptosis, inhibits T cell proliferation and IFNγ production 21, 22
PEDF Suppresses VEGF expression 47
TGF-β Inhibits NK cell-mediated cytolysis of MHC class I-negative cells, Suppresses T cell activation 31
TRAIL Promotes T cell apoptosis and proliferation of Tregs 27–29
TSP-1 Inhibits APC maturation and migration, and T cell allosensitization 25
VEGFR-1 Inhibits the mitogenic activity of VEGF-A on VECs 40
VEGFR-2 Inhibits the angiogenic activity of VEGF-C 44
VEGFR-3 Inhibits hemangiogenesis and lymphangiogenesis, decoy non-signaling receptor for VEGF-C and VEGF-D 41, 43
VIP Suppresses T cell activation and proliferation 34
*
Listed alphabetically; α-MSH, alpha-melanocyte stimulating hormone; CGRP, calcitonin gene-related peptide; CRP, complement regulatory 
proteins; IDO, indoleamine 2,3-dioxygenase; IL-1Ra, interleukin-1 receptor antagonist; MIF, macrophage migration inhibitory factor; PDL-1, 
programmed death ligand-1; PEDF, pigment epithelium-derived factor; TGF-β, transforming growth factor-beta; TRAIL, tumor necrosis factor-
related apoptosis-inducing ligand; TSP-1, Thrombospondin-1; VEGFR, vascular endothelial growth factor receptor; VIP, vasoactive intestinal 
peptide.
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